Zimbabwe has turned down a significant American health deal worth 367 million US dollars (£272m) spanning five years over the United States' request for confidential data.
This move became public after a internal memorandum from December was leaked, which showed President Emmerson Mnangagwa deemed the agreement was "skewed".
An official representative later clarified that the US was demanding access to genetic material for scientific study and commercial gain but was not willing to share the resulting advantages from future vaccines.
"We will now turn to the difficult and regrettable task of ending our health assistance in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont in a statement.
The US Embassy noted the United States had furnished over $1.9bn for health programmes to Zimbabwe over the last twenty years.
A medical body in Zimbabwe has called for continued dialogue to reach a agreement acceptable to all parties so the country's critical HIV treatment initiative can be sustained.
Wider Background
Zimbabwe's decision comes after a similar situation in Kenya, where a high court halted a similar health funding agreement after concerns were filed about the safety of citizens' medical information.
Since returning to the presidency last year, US President Donald Trump has drastically cut foreign aid and closed the key foreign aid agency.
The agency had overseen assistance for the US government, but Trump claimed its expenditure was "wasteful" and his government was seeking government-to-government agreements to enhance openness and accountability.
As per reports, Sixteen nations in Africa have so far signed these new health pacts, constituting over $18.3bn of fresh investment.
Details of the Declined Agreement
The money for Zimbabwe would have supported "combating HIV/Aids, TB, malaria, maternal and child health, and preparing for epidemics".
"We believe this partnership would have delivered immense benefits for the people of Zimbabwe, particularly the 1.2 million men, women and children currently on HIV treatment through US-supported programmes," the Ambassador said.
However, official spokesman Nick Mangwana said the arrangement was "asymmetrical".
"The proposal required Zimbabwe to share its biological resources and data for a long time, with no corresponding assurance of access to any scientific breakthroughs – like new medicines or tests – that could result from that shared data," Mangwana explained.
"In essence, our nation would provide the raw materials for scientific discovery with no assurance that the final treatments would be accessible to our people if a future pandemic emerge."
National Interest and Global Health
Mangwana further pointed out that the US's withdrawal from the World Health Organization (WHO) and its push of bilateral deals were disrupting frameworks already established via the global organization.
Mangwana gave as an example its Pandemic Benefit-Sharing scheme created to deal with future pandemics.
"This mechanism is intended to guarantee that when a nation contributes its data, the resulting advantages – including vaccines and treatments – are distributed fairly, not commercialised exclusively by those with the resources to develop them."
Zimbabwe's reservations over the US deal "are not meant as hostility towards the US," he added.
"We are open to continued dialogue with our American counterparts on how subsequent collaboration might be structured in a manner that respects the sovereignty and interests of each country."
Medical Community Reaction
A leading public health body expressed it understood the official position, but urged that negotiations need to persist given that much of the nation's HIV programmes were funded by international support.
"If technical issues exist, including those relating to data governance or agreement terms, these can often be resolved via technical clarification and mutually agreed protections," it said.
This impasse underscores the ongoing debate between receiving vital foreign assistance and safeguarding a country's data in an increasingly data-driven world.